PRNewswire: March 14, 2017 – SAN DIEGO, CA, U.S.A. – OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that they have entered into a technology access program (TAP) agreement with Inhibrx, LP, a privately…
